Gene Therapy AMT-130 Shows Dramatic Slowing of Huntington’s Disease

Gene Therapy AMT-130 Shows Dramatic Slowing of Huntington’s Disease

By, Admin 30 September 2025

A new gene therapy, AMT-130, has delivered promising results for Huntington’s disease, according to a phase I/II study supported by NIHR.

Key Findings

  • Slowed disease progression: High-dose patients showed 75% less progression over 36 months compared to a historical cohort from Enroll-HD.
  • Motor and cognitive benefits: Participants experienced slower degeneration in movement, thinking, and daily functioning.
  • Safety: AMT-130 was generally well-tolerated, with a manageable safety profile.

Study Details

  • Conducted at NIHR UCLH Clinical Research Facility and other UK sites.
  • Lead neurosurgeries by Professor Liam Gray, Advanced Neurotherapies Centre, Cardiff.
  • Scientific lead: Professor Sarah Tabrizi, UCLH, supported by the Biomedical Research Centre.
  • 29 patients completed up to 36 months; 12 received high-dose therapy.

Why It Matters

Huntington’s disease is a fatal genetic disorder affecting movement, thinking, and behaviour, with 8,000 people living with it in the UK. Until now, no treatments could meaningfully slow disease progression.

Professor Tabrizi called the results “the most convincing in the field to date”, while Professor Edward Wild described it as “the dawn of a new age for families impacted by Huntington’s disease.”

AMT-130 is the first gene therapy tested in humans for Huntington’s and represents a potentially disease-modifying treatment, offering hope to patients and families after decades of research.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!